Search

Additional file 1. Table S1. Intervention effects on cognitive functioning. Table S2. Intervention effects on cognitive functioning, per protocol. Table S3. Intervention effects, separately for patients with and without endocrine therapy. Table S4. Intervention effects, separately for patients of different age categories (30-44, 45-59, 60-75 years). Table S5. Intervention effects, separately for patients of with pre- and peri- menopausal status and patients with postmenopausal status. Table S6. Intervention effects on cognitive functioning, stratified for low versus high levels of fatigue measured with the EORTC QLQ C-30 fatigue scale. Table S7. Intervention effects on patient-reported outcomes.

The aim of the current study is to develop solid, semisolid or liquid form of radionuclide labeled thymoquinone glucuronide conjugated magnetite nanoparticles those targets to the tumor for diagnosis and therapy of cancer. For this purpose, thymoquinone (TQ), a molecule present in the seeds of Nigella (Nigella sativa) used to enhance the affinity of the drug to the tumor cells. TQ was isolated from its microsomes and an enzymatic method applied to synthesize beta glucuronic acid derivatized thymoquinone glucuronide (TQG). TQG attached magnetic nanoparticles (TQG-Fe3 O4). TQG- Fe3 O4 were radiolabeled with 125I and (125I-TQG- Fe3 O4) its cytotoxic effect and in vitro affinity was investigated. The IC50 values of TQG- Fe3 O4 were found 27.31, 18.68, 11.88 (µg/mL) respectively 24, 48 and 72 hours against A549 cell line by WST-8 test as a colorimetric way. Incorporation ratios of TQG- Fe3 O4 with A549 cells is the highest levels. It is seen that TQG-Fe3O4 could inhibit the apoptosis on A549 cells but, there is no apoptotic effect of the samples on BEAS-2B cells. Size distribution, cellular uptake and toxicity characteristics of TQG- Fe3 O4 in this study maintains a useful targeted delivery system in lung cancer diagnosis and therapy. © 2018, İstanbul Medipol University. All rights reserved., 113S922, This project was financially supported by Turkish Scientific Research Council-Health Sciences Research Support Group (TUBİTAK-SBAG; Project No: 113S922), Ankara, TURKEY.

Objectives Identification of biomarkers associated with clinical benefit may be crucial in establishing optimal treatment choice for patients with squamous cell carcinoma (SCC) of the lung after first-line chemotherapy. In this study, the ability of the VeriStrat serum protein test to predict differential clinical benefit with afatinib versus erlotinib, and the association of VeriStrat status with clinical outcomes irrespective of EGFR-TKI used, was assessed in a retrospective analysis of the phase III LUX-Lung 8 trial. Materials and methods Pretreatment plasma samples were analyzed using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Spectra were evaluated to assign a VeriStrat ‘Good’ (VS-G) or VeriStrat ‘Poor’ (VS-P) classification. Overall survival (OS), progression-free survival, and other endpoints were assessed with respect to pretreatment VeriStrat status; OS was the primary efficacy variable. Outcomes with other efficacy endpoints were similar. Results Of 795 patients randomized in LUX-Lung 8, 675 were classified (VS-G: 412; VS-P: 263). In the VS-G group, OS was significantly longer with afatinib versus erlotinib (HR 0.79 [95% CI: 0.63–0.98]). In the VS-P group, there was no significant difference in OS between afatinib and erlotinib (HR 0.90 [0.70–1.16]). However, there was no interaction between VeriStrat classification and treatment group for OS (pinteraction = 0.5303). OS was significantly longer in VS-G versus VS-P patients, both in the overall VeriStrat-classified population (HR 0.41 [0.35–0.49]) and afatinib-treated patients (HR 0.40 [0.31–0.51]). Multivariate analysis showed that VeriStrat was an independent predictor of OS in afatinib-treated patients, regardless of ECOG PS or best response to first-line chemotherapy. Conclusion VS-G classification is strongly associated with favorable survival outcomes with either afatinib or erlotinib compared with VS-P classification. In VS-G patients, survival outcomes with afatinib are superior to those with erlotinib. VeriStrat classification may guide treatment decisions in patients with SCC of the lung. ClinicalTrials.gov registration number: NCT01523587. © 2017

Eosinophilia is defined as the amount of eosinophils more than 700/mm3 at the peripheral blood. There are many causes of eosinophilia, but the two most common ones are the parasitic infections and allergic disorders. Eosinophilia can be seen in hematological malignancies such as Hodgkin's disease and mycosis fungoides, and occured rarely in solid organ malignancies. In this article, we present a case with gastric carsinoma associated with eosinophilia that disappeared dramatically after chemotherapy.

In this article we attempt to cast light on Alevi politics in Turkey, mainly the diverse political orientations regarding Alevilik.' We note the differential political power the groups with different political orientations hold and their varied positionings vis-a-vis the Turkish state, as well as the competing political agendas they offer, and to which groups in the Alevi public these political agendas appeal and why. Alevilik is the second major religious formation after Sunnilik in Turkish society. There is no accurate information and consensus on the number of Alevis in the society because of the assimilative politics of the state since Ottoman times, as well as the tendency of the Alevi to hide their identities. Their estimated number by different sources however ranges from at least 10 per cent to over a quarter of the total population.2 Since the last decade Alevis have become more visible in society, and they have been more active in the political arena. We can talk about the re-politicization (for some, revivalism)3 of Alevilik in the Turkish civil society where the popular and academic literature on various aspects of Alevilik increased.4 Political debates initiated by various Alevi communities and popular demands of the Alevi population were carried onto the public sphere. With the development of and quantitative increase in the media in Turkey, Alevi identities found new channels to express themselves. General reasons for this re-politicization of Alevilik can be identified:5 Firstly, there is the fall of Communism and its effect on those Leftists close to Alevilik. This resulted in the redefinition of Alevilik as an alternative social movement (and clearly not a religious one). Secondly, the rise of Sunni political Islam has made the Alevi population, along with Sunni Kemalists, organize themselves as a counterforce against it, defending Kemalist principles, and particularly secularism. This point is also addressed by Kehl-Bodrogi who argues that the timing of the reawakening of Alevism was no coincidence: (The reawaking of Alevism) occurred at the peak of the political struggles to preserve the laicistic legacy of Kemalism. In this situation the Alevis were in a position to present themselves to secular Turkey

WOS: 000444765300010, PubMed ID: 29902295, IMPORTANCE Treatment choice for lung squamous cell carcinoma could be aided by identifying predictive biomarkers. OBJECTIVE To assess whether patient outcomes in the LUX-Lung 8 trial were associated with ERBB gene family member aberrations in tumor specimens. DESIGN, SETTING, AND PARTICIPANTS Ad hoc secondary analysis of the LUX-Lung 8 trial conducted at 183 centers in 23 countries from March 30, 2012, to January 30, 2014. Eligible patients had stage IIIB or IV lung squamous cell carcinoma with progressive disease after 4 or more cycles of platinum-based chemotherapy. Tumor genetic analysis (TGA) was performed using next-generation sequencing in a cohort enriched for patients with progression-free survival (PFS) of more than 2 months. Epidermal growth factor receptor (EGFR) expression levels were assessed by immunohistochemistry in a separate cohort of patients from the LUX-Lung 8 population. Associations of PFS and overall survival (OS) with ERBB gene alterations and EGFR expression levels were assessed. This analysis was conducted from February 26, 2015, to June 12, 2017. INTERVENTIONS Patients were randomized 1:1 to treatment with afatinib dimaleate (40mg/d; n = 398) or erlotinib hydrochloride (150mg/d; n = 397). MAIN OUTCOMES AND MEASURES Overall survival, PFS, pooled and individual ERBB gene mutations, ERBB copy number alterations, and EGFR expression. RESULTS Tumor specimens from 245 patients were eligible for next-generation sequencing (TGA subset: 132 patients treated with afatinib; 113 patients treated with erlotinib). In this population, outcomes were improved with afatinib vs erlotinib treatment (PFS: median, 3.5 vs 2.5 months; hazard ratio [HR], 0.69; 95% CI, 0.51-0.92; P = .01; OS: median, 8.4 vs 6.6 months; HR, 0.81; 95% CI, 0.62-1.05; P = .12). Of 245 patients in the TGA subset, 53 (21.6%) had tumors with 1 or more ERBB mutations. Among afatinib-treated patients, PFS (median, 4.9 vs 3.0 months; HR, 0.62; 95% CI, 0.37-1.02; P = .06) and OS (median, 10.6 vs 8.1 months; HR, 0.75; 95% CI, 0.47-1.17; P = .21) were longer among those with ERBB mutation-positive disease than among those without. The presence of HER2 mutations was associated with favorable PFS and OS following afatinib vs erlotinib treatment. There was no apparent association between copy number alteration or EGFR expression level and outcome. CONCLUSIONS AND RELEVANCE Next-generation sequencingmay help identify patients with lung squamous cell carcinoma who would derive additional benefit from treatment with afatinib. The role of ERBB mutations, particularly HER2 mutations, as predictive biomarkers for afatinib treatment in this setting warrants further evaluation., Boehringer IngelheimBoehringer Ingelheim, This study was funded by Boehringer Ingelheim.